Adrenocortical carcinoma (ACC) is a rare, aggressive malignancy that generally conveys a poor prognosis. Currently, surgical resection is considered the lone curative treatment modality. In addition, the low prevalence of ACC has limited effective clinical trial design to develop evidence-based approaches to ACC therapy. The proper role of radio- and chemotherapy treatment for ACC is still being defined. Similarly, the molecular pathogenesis of ACC remains to be fully characterized. Despite these challenges, progress has been made in several areas. After years of refinement, an internationally accepted staging system has been defined. International collaborations have facilitated increasingly robust clinical trials, especially regarding agent choice and patient selection for chemotherapeutics. Genetic array data and molecular profiling have identified new potential targets for rational drug design as well as potential tumor markers and predictors of therapeutic response. However, these advances have not yet been translated into a large outcomes benefit for ACC patients. In this paper, we summarize established therapy for ACC and highlight recent findings in the field that are impacting clinical practice.
1. Introduction
Adrenocortical carcinoma (ACC) is a rare, aggressive malignancy that features a correspondingly poor prognosis. The pathogenesis of ACC is poorly understood, especially at the molecular level, as the rarity of the disease makes comprehensive study difficult. As a result, therapeutic options for ACC are currently limited, with medical and radiation therapy remaining complementary to surgery, which is currently the lone curative modality for ACC. Additionally, apart from surgery, treatment for ACC has never been standardized due to the lack of large randomized trials. However, ACC therapy is now evolving. Novel research and the increasing quality of clinical trials may improve available treatment options and outcomes for ACC patients as novel chemotherapeutic agents are introduced and long-standing drug regimens are reassessed.
An overall incidence of 0.5–2 per 1 million cases of ACC have been reported annually worldwide [1, 2]. ACC shows a slight female gender preference and a bimodal age distribution with the first peak in children less than five years of age and the second peak in the fourth to fifth decade of life. Most cases of ACC are sporadic, although some familial cancer syndromes, such as Li-Fraumeni and Beckwith-Wiedemann syndromes, are associated with an increased incidence of ACC [3]. Approximately 60% of patients present with symptoms of excess hormone secretion, most commonly in the form of cortisol hypersecretion (most commonly, hypercortisolism: Cushing’s syndrome), with or without virilization due to accompanying androgen excess. Progression is rapid, generally with less than 12 months elapsing from the first clinical changes to advanced Cushing’s syndrome [4, 5]. Interestingly, hormonal secretion patterns can vary according to size, differentiation, and stage of the tumor. In cases without clinical hormone overactivity, the most common presentation is related to tumor growth and encroachment on the surrounding viscera, with symptoms such as abdominal discomfort, back pain, and nausea or vomiting. Despite this, overproduction of hormonal precursors is detectable in virtually all cases of ACC, due to defective steroidogenesis within the tumor.
Adrenocortical malignancy can be, regardless of biochemical activity, notoriously difficult to diagnose. In tumors confined to the adrenal gland, the diagnosis may be unclear even after pathological assessment following surgical resection; a widely validated scoring classification (Weiss criteria) is employed in such cases to improve accuracy of diagnosis [6]. On computed tomography (CT), ACC can demonstrate central tumor necrosis, calcifications, and also tends to be larger and more heterogeneous. Reliance on size alone can be misleading, as the widely utilized 4 cm cutoff has a sensitivity of only 81% for ACC. However, ACCs exhibit a significantly higher density on noncontrast CT than adenomas, with a specificity for differentiating adenoma from carcinoma of 100% and 96.9% using 10 and 20 Hounsfield unit cutoffs, respectively [7–9]. Steroid profiling, which is distinct from routine biochemical analysis for adrenal hormone production, is another promising method for differentiating adrenocortical adenomas (ACAs) from ACCs. By using gas chromatography/mass spectrometry to analyze the steroid profiles in 24-hour urine samples of patients with ACCs or ACAs versus control patients, Arlt et al. have identified several metabolites with diagnostic utility. In a retrospective study, their algorithm demonstrated a sensitivity and specificity of 88% for differentiating ACC and ACA when using the nine metabolites identified to have the most diagnostic significance, which exceeds the accuracy of CT alone [10].
Survival for patients with ACC is poor and related to stage at time of diagnosis, which is often advanced. Up to 70% of patients present with extra-adrenal disease [11]. Overall cancer-specific mortality (CSM) rates have been reported between 16% and 38% [1, 12, 13]. Five-year survival for patients with disease confined to the adrenal gland is size-dependent and varies from 61 to 82%. Those with distant metastases at diagnosis have a five-year survival of only 18% [14]. Improved radiographic imaging and surveillance of incidentally discovered adrenal masses have resulted in earlier detection and earlier staging at diagnosis.
2. Staging
The TNM staging system is considered the most important tool in prognostic stratification and therapy planning and stratifies cancer patients by survival based on clinical status [2, 12–14]. However, due to the low incidence of ACC and resultant inability to validate ACC staging and survival with any statistical reliability, no TNM classification was available for ACC until recently. Multiple different staging systems were used prior to that time, the most widespread being devised in 1978 by Sullivan, who modified the original McFarlane staging system [2, 15–17]. In 2004, the International Union Against Cancer (UICC) and the World Health Organization (WHO) proposed a new staging system based on Sullivan-McFarlane criteria (Table 1) [18].
Comparison UICC and ENSAT staging systems for ACC.
Stage
UICC/WHO 2004
ENSAT 2008
I
T1, N0, M0
T1, N0, M0
II
T2, N0, M0
T2, N0, M0
III
T1-2, N1, M0
T1-2, N1, M0
T3, N0, M0
T3-4, N0-1, M0
T1–4, N0-1, M1
T1–4, N0-1, M1
IV
T3, N1, M0
T4, N0-1, M0
T1: tumor ≤ 5 cm; T2: tumor > 5 cm; T3: tumor infiltration in surrounding tissue; T4: tumor infiltration in adjacent organs [ENSAT additionally the presence of a tumor thrombus in the Vena Cava or Vena Renalis]; N0: absence of positive lymph nodes; N1: presence of positive lymph nodes; M0: absence of distant metastases; M1: presence of distant metastasis.
To evaluate the UICC system, a large European study examined 416 patients and found a low correlation between five-year disease-specific survival and stage for patients with stage II and III disease. A new staging system was therefore proposed by the European Network for the Study of Adrenal Tumors (ENS@T) consisting of the following major changes.
Existence of a thrombus in the inferior vena cava or adjacent renal veins upstages the tumor to T4, with a corresponding grading of stage III.
Stage IV tumors are exclusively defined as those with distant metastases.
The ENS@T criteria have been validated in a large North American trial evaluating 573 patients, with a statistically significant difference in cancer-specific mortality now observed between stage II and III patients when the new criteria were applied. Furthermore, 3-year accuracy in predicting CSM rates improved for all patients regardless of stage from 79.5% to 83.0%, when the ENS@T rather than UICC criteria were employed.
3. Surgery3.1. Established Therapy
In newly diagnosed cases of ACC, feasibility of surgical resection is the most important contributor to overall survival. While successful treatment of ACC requires a multidisciplinary approach, complete surgical resection is mandatory if possible for patients presenting with stage I to stage III disease. The goal of surgery is R0 resection of the tumor and any involved tissues or viscera in an en bloc fashion. Patients undergoing successful resection have a five-year survival of 40–50%, while median survival of unresectable patients is less than one year [17, 34, 35]. When stratified by stage at time of resection, 5-year disease-specific survival was found to be 82% for stage I disease, 58% for stage II, 55% for stage III, and 18% for stage IV [14].
There is consensus that resection should be performed by an experienced multidisciplinary team [36]. This is especially crucial in the management of patients with biochemically active tumors. Intraoperatively, maintaining tumor capsule integrity and preventing tumor spillage are key considerations [4]. Notably, presence of tumor thrombi and vascular invasion are not contraindications to resection. In cases with extensive vascular involvement, usage of cardiopulmonary bypass can facilitate successful resection [37]. A transabdominal, open surgical approach allows maximal exposure. This facilitates en bloc excision of tumor and other involved organs, maintenance of the tumor capsule, and effective vascular control when necessary.
There is an ongoing debate on the role of lymphadenectomy. A retrospective analysis of the data from the German ACC registry by Reibetanz et al. indicated that locoregional lymph node dissection improved tumor staging and lead to a favorable oncologic outcome in patients with localized ACC [38]. For recurrent disease, reoperation with the goal of radical resection or tumor debulking is beneficial in those patients who are surgical candidates [35, 39]. During reoperation, complete resection is again crucial, resulting in a mean survival time of 74 months versus 16 months in those with incomplete resections [35]. In some patients that display unresectable disease at the time of diagnosis, debulking may be beneficial in tumors [36]. Debulking may provide relief from symptoms of hormonal excess and facilitate additional treatment options [20, 40]. Conversely, patients with widely metastatic disease or rapidly enlarging tumors at diagnosis are better managed with medical palliation only.
3.2. Emerging Trends
Since its introduction in 1992, laparoscopic adrenalectomy (LA) has become the treatment of choice for benign adrenal tumors due to improvements in postoperative analgesia use, cosmesis, and length of hospital stay [41, 42]. Resection of ACC via a laparoscopic approach, while technically feasible, remains highly controversial. Initial reports evaluating laparoscopic versus open adrenalectomy in ACC patients noted both higher rates of recurrence and shorter disease-free survival in those with laparoscopic resections [19, 33]. Notably, those undergoing laparoscopic resection demonstrated a substantially increased rate of local recurrence and peritoneal carcinomatosis compared to recurrences in those undergoing open resection (83% versus 43% in one study), suggesting loss of capsule integrity and port site seeding as potential causes of the poorer outcomes seen with laparoscopy [19]. Conversely, several more recent studies have found comparable outcomes between laparoscopic and open approaches in ACC resection (Tables 2 and 3). One study evaluating 152 patients undergoing either laparoscopic (n=35) or open (n=117) adrenalectomy for ACC found identical oncologic outcomes. However, it was limited to patients with tumor size ≤ 10 cm and 12 patients undergoing laparoscopic resection required conversion to an open approach [32]. An Italian study demonstrated similar findings in a cohort limited to patients with a stage I and II disease only [43]. In general, superior surgical outcomes following adrenalectomy are observed in centers with high-volume surgeons and considerable expertise; this is especially true in adrenalectomy for ACC [44, 45].
Retrospective series of open adrenalectomies.
Author
Total number of malignant cases
Mean tumor size (cm)
Duration of followup (months)
Recurrence rate
Comments
Gonzalez et al., 2005 [19]
133 ACC
NR
28
51%
Median survival duration: 34 months
Crucitti et al., 1996 [20]
91 ACC
NR
NR
15%
Median survival duration: 28 months
Terzolo et al. [21, 22]
55 ACC
10
67
90
Median survival duration: 52 months
75 ACC
10
43
73
Median survival duration: 67 months
Icard et al., 2001 [17]
253 ACC
12
NR
NR
5 year survival: 38%
Kendrick et al., 2001 [23]
58 ACC
12.5
53
51
5 year survival: 37%
Summary of series of laparoscopic adrenalectomies for adrenal malignancies.
Author
Total number of LA
Total number of malignant cases
Mean tumor size (cm)
Duration of followup (months)
Recurrence rate
Comments
Henry et al., 2002 [24]
233
6 ACC
7.4
47
17%
1 dead of disease
Porpiglia et al., 2004 [25]
205
6 ACC
6.9
30
0%
1 dead of cerebrovascular accident
Corcione et al., 2005 [26]
100
2 ACC
8.5
13.6
50%
Both patients alive, one has still disease
Gonzalez et al., 2005 [19]
6
6 ACC
5.3
28
100%
2 are still alive with disease, remaining 4 died of disease
Palazzo et al., 2006 [27]
391
3 MP
6.8
34
33%
1 dead of disease
Lombardi et al., 2006 [28]
79
4 ACC3 MP
5.9
23
29%
4 alive disease free, 2 alive with disease and one dead of liver failure
Liao et al., 2006 [29]
210
4 ACC
6.2
39
25%
1 alive disease free, 1 alive with disease and 2 died of disease
Nocca et al., 2007 [30]
131
4 ACC
8.5
34
25%
3 alive disease free, 1 died of metastatic disease
Ramacciato et al., 2008 [31]
18
2 ACC
8.3
44
0%
Alive and disease free
Brix et al., 2010 [32]
35
35 ACC
6.2
39
77%
37% of patients died from ACC
Miller et al., 2010 [33]
17
17
7.0
36
20%
Not investigated, but authors concluded that the mean time to local recurrence was shorter in LA compared to the open group
Historically, radiation therapy (RT) has not been considered effective in treatment of primary ACC [46–49]. ACC is not an overly radiosensitive tumor, and the anatomical proximity to radiosensitive viscera such as the small bowel, kidney, and spinal cord has limited the clinical utility of radiotherapy. There is a well-defined role for RT in the treatment of metastatic ACC, especially in bony disease [50, 51]. Furthermore, radiotherapy can improve symptoms in patients with bulky abdominal tumors that are unresectable [52]. In a study of 91 patients in the German ACC registry, a response rate of 57% was noted in patients receiving palliative radiotherapy [53], and an investigation of the Dutch ACC registry showed that ACC can be radiosensitive and patients with advanced disease can benefit from it [54].
4.2. Emerging Techniques
The role of radiotherapy in an adjuvant therapy for ACC remains controversial. Improvements in technology and radiotherapy protocols (specifically, stereotactic body radiation therapy) have resulted in superior morbidity profiles compared to historical controls due to improved targeting and lower nontumor dosing. However, there is still no prospective evidence supporting radiotherapy in an adjuvant setting. The best current evidence advocates for the usage of radiotherapy for local control in unresectable disease and after resection in certain cases [55]. In general, adjuvant radiotherapy has been advocated as a means to reduce the high incidence of local recurrence observed in ACC. A recent North American study evaluating surgery alone versus surgery and radiotherapy found that those treated with surgery alone had an odds ratio for local recurrence of 4.7 versus those who received adjuvant radiation [56]. These data concur with a European study that also found increased local recurrence in the surgery alone group [57]. However, that study failed to demonstrate either a disease-free or overall survival benefit.
The lack of strong evidence supporting radiotherapy has resulted in a variety of treatment recommendations. The German ACC group currently recommends radiotherapy in the following cases [53]:
all patients with incomplete (R1 or R2) or uncertain (Rx) resections,
all patients with stage III disease regardless of resection adequacy,
strong consideration in cases of >8 cm tumor size, Ki-67 index > 10%, and invasion of adjacent vasculature, even in cases of complete resection.
Prospective data are needed to fully define the role of radiotherapy in the adjuvant setting for ACC. Despite this, the available evidence supports treatment in patients with incomplete resection, stage III disease, or in the palliative setting.
5. Medical Therapy
Medical therapy for ACC takes two forms. Cytotoxic agents, of which mitotane (1,1-dichloro-2(o-chlorophenyl)-2-(p-chlorophenyl)ethane) is the prototype, have been the mainstay of ACC chemotherapeutics for decades and have been studied in adjuvant, recurrent, and palliative settings. Disagreement persists over the most efficacious treatment regimen in each role. Biologic pharmaceuticals have recently been introduced into practice for ACC treatment based on rational selection of molecular targets. Numerous biologic agents are currently being evaluated in clinical trials.
6. Adjuvant Systemic Therapy
Mitotane is a derivate of the insecticide DDT and is directly toxic to the adrenocortical parenchyma. It has been the mainstay of systemic ACC treatment since the 1960s. Clinical response to mitotane is not universal, possibly due to the need for metabolic transformation of mitotane for therapeutic action [58]. The therapeutic index of mitotane is narrow; up to 80% of patients develop side effects, some of which can lead to cessation of therapy [59]. Nausea, emesis, and other gastrointestinal symptoms are most common, but neurologic toxicity can occur as well, especially at high dose ranges. A serum concentration of 14–20 mcg/mL is usually considered therapeutic [13, 60–62]. Despite this, the optimum dose regimen is unknown. A therapeutic range can be achieved with a low-dose scheme designed to minimize toxicity [21]. However, most recurrences in the adjuvant setting occur less than six months postoperatively and the time to achieve effective serum levels is increased when utilizing a low-dose regimen [63, 64].
Currently, no prospective clinical trials exist evaluating adjuvant mitotane use. Several earlier observational studies did not report improved overall or disease-free survival with adjuvant mitotane use [65, 66], while more recent studies have noted a modest benefit [23, 67]. The best available evidence comes from a large European retrospective study evaluating 177 patients with ACC, with 47 patients receiving surgery and adjuvant mitotane and 130 receiving surgery alone. Recurrence-free survival was significantly improved in the treatment group. However, the surgery alone group had a higher incidence of advanced disease, which the authors controlled for by employing a multivariate statistical model which continued to demonstrate a benefit to mitotane use [22]. As such, the decision to administer adjuvant mitotane remains controversial. A panel of international experts in 2008 unanimously recommended adjuvant mitotane in patients with potential residual disease (R1 or Rx resection) or greater than 10% Ki67 positivity on pathologic examination [68]. Similarly, the same panel did not consider mitotane to be mandatory to patients with stage I or II disease who underwent histologically proven R0 resection with Ki67 indices less than 10%. The panel was undecided on whether to offer adjuvant therapy to stage III ACC patients following an R0 resection. Currently, a prospective randomized trial evaluating adjuvant mitotane use is recruiting patients in several European centers with the goal of improving future treatment algorithms.
7. Systemic Therapy in Locally Advanced and Metastasized Disease
Standard of treatment in patients with unresectable or metastasized ACC previously consisted of mitotane alone or in combination with other cytotoxic drugs [36, 69]. Generally, prognosis is poor in this patient population, although reports of long-term survival exist [35, 70, 71]; it is unclear whether this is due to favorable tumor biology or therapeutic intervention. Studies investigating mitotane alone in these patients have demonstrated a response rate of 19–33%, but with minimal survival benefit in responders (9 months in the largest trial) [60, 62, 72]. Mitotane in combination with standard cytotoxic agents has been investigated, with the two most popular regimens of mitotane-streptozocin (M-Sz) and mitotane etoposide/doxorubicin/cisplatin (M-EDP) having previously been investigated in phase II trials. In separate studies, an objective responsive rate of 36% was observed in 22 patients with advanced ACC receiving M-Sz [73] and in 53% of 28 patients receiving M-EDP [74]. Recently, the FIRM-ACT (First International Randomized Trial in Locally Advanced and Metastatic ACC Treatment) trial was released, which is a landmark randomized controlled trial comparing M-Sz and M-EDP in 304 patients with advanced ACC [75]. The trial found M-EDP statistically superior to M-Sz in terms of objective tumor response (23.2 versus 9.2%, resp.), progression-free survival (5.0 versus 2.1 months), and proportion of patients without progression at one year (23.2% versus 9.2%). Tumor burden was monitored by serial CT scans every eight weeks. Overall survival at the time of the study’s conclusion favored M-EDP (14.8 months versus 12.0 months) without reaching statistical significance. The study also included an elegantly designed nested trial evaluating each regimen as a second-line regimen, whereas patients with treatment failure in their original group were given the alternative regimen (but still underwent primary endpoint analysis in an intent-to-treat manner). As second-line therapies, the efficacy of both regimens was similar to their efficacy as first-line therapy, with M-EDP showing superior antitumor efficacy and progression-free survival. Notably, the authors found no statistically significant difference in quality of life or rate of adverse events between the two treatment groups. As such, selection of systemic treatment for recurrent or metastatic ACC should favor M-EDP as the first-line therapy of choice in the future.
8. Targeted Therapy
Ongoing research into the oncogenesis of ACC has increased knowledge of the molecular mechanisms of ACC tumor growth and also identified potential targets for drug development. Gene transcriptome analysis has elucidated significant differences between the gene expression profile of ACC and benign adrenocortical adenomas with a large number of genes demonstrating differential or tumor-specific expression [76–80]. Szabó et al. analyzed microarray data from several studies and found a significant upregulation of genes involved in the cell cycle, growth factors and receptors and, simultaneously, a downregulation of genes that play a role in steroidogenesis, metabolism, and cell transport in ACC compared to benign disease [81]. Alterations in expression of the insulin-growth factor genes (IGF-1 and -2) are one of the most common mutations in ACC and one of the earliest recognized [82, 83]. Furthermore, additional growth factors have been implicated in ACC such as epidermal growth factor (EGF), transforming growth factor-α (TGF-α), and vascular endothelial growth factor (VEGF). Many of the receptors for these ligands belong to the tyrosine kinases receptor superfamily, inhibitors of which are already in clinical use for other malignancies [84]. In general, initial results utilizing tyrosine kinase inhibitors and other targeted therapeutics for ACC have been unable to improve upon the current standard of care as yet [4, 85–88]. The following section summarizes the current experience with selected agents that are in clinical investigation or have been promising in preclinical studies. Active clinical trials utilizing targeted therapy for ACC are listed in Table 4.
Ongoing Clinical Trials that test the Target Therapies.
Study
Target
ID
Purpose
Status
Mitotane with or without IMC-A12 in treating patients with recurrent, metastatic, or primary adrenocortical cancer that cannot be removed by surgery
IGF1R
NCT00778817
This randomized phase II trial compares the combination of mitotane and IMC-A12 with mitotane alone in the treatment of recurrent, metastatic, or primary adrenocortical cancer that cannot be removed by surgery
Recruiting
A study of OSI-906 in patients with locally advanced or metastatic adrenocortical carcinoma (GALACCTIC)
IGF1R
NCT00924989
A multicenter, randomized, double-blind, placebo-controlled, phase III study of single-agent OSI-906 in patients with locally advanced/metastatic adrenocortical carcinoma who received at least 1 but no more than 2 prior drug regimens
Ongoing not recruiting
Phase II trial of ZD1839 (Iressa) in patients with nonresectable adrenocortical carcinoma
VEGFR
NCT00215202
This phase II trial investigates the effect of Iressa in patients with nonresectable adrenocortical cancer who have previously been treated with one other form of systemic therapy (either Mitotane or chemotherapy).
Completed
Phase II Study of Axitinib (AG-013736) With Evaluation of the VEGF-Pathway in Metastatic, Recurrent or Primary Unresectable Adrenocortical Cancer
Multikinase
NCT01255137
To evaluate the effectiveness of axitinib in individuals who have adrenocortical cancer that is inoperable and has not responded to standard treatments
Recruiting
(i) VEGFR
(ii) PDGFR
(iii) KIT
Sunitinib in Refractory Adrenocortical Carcinoma (SIRAC)
Multikinase
NCT00453895
The primary objective of this trial is to estimate the response (defined as progression-free survival of ≥12 weeks) rate associated with Sunitinib treatment in patients advanced ACC progressing after cytotoxic chemotherapy
Unknown
(i) VEGFR
(ii) PDGFR
(iii) KIT
Sorafenib Plus Paclitaxel in adreno-cortical-cancer patients (PAXO)
Multikinase
NCT00786110
The aim of this phase II trial is to evaluate the clinical benefit and toxicity of the combination of Sorafenib plus metronomic chemotherapy in patients with locally advanced or metastatic ACC who progressed after first or second line chemotherapy.
Unknown
(i) RAF
(ii) VEGFR
(iii) PDGFR
(iv) KIT
Clinical trial of Dovitinib in first-line metastatic or locally advanced non-resectable adrenocortical carcinom
FGFRs
NCT01514526
Non-randomized, phase II clinical trial, that investigates the use of Dovitinib in adult patients with metastatic or locally advanced non-resectable adrenocortical carcinoma, confirmed histologically
Recruiting
Cixutumumab in treating patients with relapsed or refractory solid tumors
IGF1R
NCT00831844
Phase II trial that studies the side effects and how well cixutumumab works in treating patients with relapsed or refractory solid tumors, including ACC
Recruiting
8.1. IGF Antagonists
IGF-1 and -2 are implicated in ACC development through both the phosphoinositide-3-kinase (PI3 K)-Akt and the Ras-Raf-MAP kinase pathways. Genome-wide gene expression studies have identified that overexpression of IGF-2, the ligand to the IGF-1 receptor which activates both of the above pathways, is a very consistent molecular event in the development of ACC [76, 77, 82, 89, 90]. Haluska et al. investigated an anti-IGF-1R antibody (figitumumab) in a phase I study and found it to be well tolerated and achieved stability of disease in 8 out of 14 patients (57%) [91]. The GALACCTIC trial is a phase 3 randomized, double-blinded trial investigating OSI-906, a combined inhibitor of IGF-1R and insulin receptor(IR) in patients with locally advanced or metastatic ACC who failed at least one prior drug regimen. OSI-906 has shown an antineoplastic effect in vitro [92]. The study has reached its accrual goals and is currently ongoing.
8.2. mTOR Antagonists
The mammalian target of rapamycin (mTOR) is a serine/threonine protein kinase that is involved in cell growth and proliferation that is activated in part by IGF-1R signaling via the aforementioned PI3 K-Akt pathway. The prototype mTOR inhibitor, sirolimus, has long been utilized as an antirejection drug following solid organ transplant, and mTOR inhibitors have recently been investigated in clinical trials for treating malignancies, such as renal cell carcinoma [93]. Given its association with the IGF-1R pathway known to be dysregulated in ACC, inhibition of mTOR seems an appropriate target for investigation in ACC treatment. Doghman et al. demonstrated that inhibition of mTOR signaling reduced adrenocortical tumor growth in vitro and in an in vivo mouse model in 2010 [94]. Temsirolimus, a second-generation mTOR inhibitor in combination with cixutumumab, an anti-IGF-1R antibody, has been welltolerated in phase I trials in patients with advanced tumors, including ACC [95]. Additional clinical trials are ongoing (see Table 4).
8.3. Future Targets
The canonical Wnt/β-catenin signaling pathway, involved in both human development and homeostasis, is dysregulated in a large number of human disease processes [96]. Microarray analysis has demonstrated upregulation of this pathway in ACC, and CTNNB1, the gene encoding β-catenin, is frequently mutated in adrenocortical neoplasia [97, 98]. Furthermore, CTNNB1, the gene encoding β-catenin, has been found to be frequently mutated in both ACC and adrenocortical adenomas [99]. This common mutation in both benign and malignant adrenocortical neoplasia may indicate an early step in a common pathway of tumorigenesis. Berthon et al. demonstrated a clear link between constitutive β-catenin activation and adrenal cortex dysplasia in a transgenic murine model, resulting in malignant changes such as neovascularization and local tumor invasion [100]. However, drugs effectively targeting the Wnt pathway have been slow to develop and further research identifying specific genetic targets is needed.
Steroidogenic factor (SF)-1 is an orphan nuclear receptor that has a key role in normal endocrine and gonadal development, as well as regulating steroid production in the adrenal cortex via interactions with several cytochrome P450 steroid hydroxylases in the adrenal cortex [101]. Overexpression of SF-1 has been demonstrated in ACC, especially in pediatric cases [102, 103]. Interestingly, SF-1 has been demonstrated to have a dose-dependent effect on the induction of adrenocortical cell proliferation through changes in apoptosis and cell cycle control [104]. In a mouse model, SF-1 induced adrenal hyperplasia and tumor growth. Antagonists of SF-1 inverse agonists have been identified and demonstrated inhibition of adrenocortical cell proliferation and steroidogenesis [105].
8.4. Individualized Treatment
Giordano et al. first reported transcriptional profiling of ACC in 2003. Genetic profiling of individual tumors has many potential benefits, but especially relevant to treatment of ACC is the opportunity to predict response rates to certain pharmaceutical agents and determination of prognosis. Aside from improving patient care, a secondary benefit of such information would be segregation of patients into clinical trial subgroups with others that have their specific form of disease [97]. Several molecular markers of drug sensitivity in ACC have been identified and are under investigation, as standard ACC chemotherapy is associated with significant toxicity and variable response rates characteristics [106]. For instance, ERCC1, a DNA repair protein, has previously been shown to predict resistance to platinum-based chemotherapy regimens. Less than 50% of ACCs treated with a platinum-based regimen shows a clinical response, and ACC patients demonstrating a high rate of ERCC1 expression following platinum-based chemotherapy have a significantly shortened median survival time (8 versus 24 months in low-ERCC1 patients) [107]. Additionally, a phase II trial is underway for ACC utilizing a regimen including XR9576, an inhibitor of MDR1, expression of which has been implicated in other multidrug-resistant tumors [108, 109]. Ideally, as the cost of genetic sequencing continues to fall and knowledge of the implications of specific genetic changes on treatment response and outcome improves, treatment regimens can be optimized on an individualized basis.
9. Conclusion
ACC remains a rare malignancy that has seen little improvement in overall mortality over the past two decades. Until recently, standard of care was based only on individual opinion and occasionally expert consensus. Over the past decade, international collaboration has begun to improve the management of these patients and the molecular understanding of the disease. The development of standardized staging criteria and the gradual accrual of clinical trials in treating ACC, especially with the release of the first randomized phase III trial in ACC, exemplifies the ongoing progress in clinical care of these patients. Similarly, as the genetic understanding of adrenal tumorigenesis continues to progress, more targets for future drug development are identified and evaluated. As these discoveries are translated into clinical practice, ACC therapy will move beyond historical modalities to the benefit of patients everywhere.
WajchenbergB. L.Albergaria PereiraM. A.MedoncaB. B.Adrenocortical carcinoma: clinical and laboratory observations2000884711736FassnachtM.WittekindC.AllolioB.Current TNM classification systems for adrenocortical carcinoma20103153743782-s2.0-7795758331210.1007/s00292-010-1306-1SoonP. S. H.McDonaldK. L.RobinsonB. G.SidhuS. B.Molecular markers and the pathogenesis of adrenocortical cancer20081355485612-s2.0-4574910560910.1634/theoncologist.2007-0243FassnachtM.AllolioB.Clinical management of adrenocortical carcinoma20092322732892-s2.0-6614916311310.1016/j.beem.2008.10.008ZiniL.PorpigliaF.FassnachtM.Contemporary management of adrenocortical carcinoma2011605105510652-s2.0-7996111203810.1016/j.eururo.2011.07.062WeissL. M.MedeirosL. J.VickeryA. L.Pathologic features of prognostic significance in adrenocortical carcinoma19891332022062-s2.0-0024513504BolandG. W. L.BlakeM. A.HahnP. F.Mayo-SmithW. W.Incidental adrenal lesions: principles, techniques, and algorithms for imaging characterization200824937567752-s2.0-5814920006710.1148/radiol.2493070976YoungW. F.Jr.Conventional imaging in adrenocortical carcinoma: update and perspectives201126341347HamrahianA. H.IoachimescuA. G.RemerE. M.Motta-RamirezG.BogabathinaH.LevinH. S.ReddyS.GillI. S.SipersteinA.BravoE. L.Clinical utility of noncontrast computed tomography attenuation value (hounsfield units) to differentiate adrenal adenomas/hyperplasias from nonadenomas: cleveland clinic experience20059028718772-s2.0-2004438453210.1210/jc.2004-1627ArltW.BiehlM.TaylorA. E.Urine steroid metabolomics as a biomarker tool for detecting malignancy in adrenal tumors2011961237753784PhanA. T.Adrenal cortical carcinoma-review of current knowledge and treatment practices20072134895072-s2.0-3424981119510.1016/j.hoc.2007.04.007LughezzaniG.SunM.PerrotteP.JeldresC.AlaskerA.IsbarnH.BudäusL.ShariatS. F.GuazzoniG.MontorsiF.KarakiewiczP. I.The European Network for the Study of Adrenal Tumors staging system is prognostically superior to the international union against cancer-staging system: a North American validation20104647137192-s2.0-7604909562110.1016/j.ejca.2009.12.007AllolioB.FassnachtM.Clinical review: adrenocortical carcinoma: clinical update2006916202720372-s2.0-3374495217610.1210/jc.2005-2639FassnachtM.JohanssenS.QuinklerM.Limited prognostic value of the 2004 International Union Against Cancer staging classification for adrenocortical carcinoma: proposal for a Revised TNM Classification200911522432502-s2.0-73149088410KebebewE.ReiffE.DuhQ. Y.ClarkO. H.McMillanA.Extent of disease at presentation and outcome for adrenocortical carcinoma: Have we made progress?20063058728782-s2.0-3364659377710.1007/s00268-005-0329-xSullivanM.BoileauM.HodgesC. V.Adrenal cortical carcinoma197812066606652-s2.0-0018249921IcardP.GoudetP.CharpenayC.AndreassianB.CarnailleB.ChapuisY.CougardP.HenryJ. F.ProyeC.Adrenocortical carcinomas: surgical trends and results of a 253-patient series from the French Association of Endocrine Surgeons Study Group20012578918972-s2.0-003491709710.1007/s00268-001-0047-yDeLellisR. A.2004Lyon, FranceIARC PressGonzalezR. J.ShapiroS.SarlisN.Vassilopoulou-SellinR.PerrierN. D.EvansD. B.LeeJ. E.InabnetW. B.LibuttiS. K.ChenH.DuhQ. Y.WilhelmS.Laparoscopic resection of adrenal cortical carcinoma: a cautionary note20051386107810852-s2.0-2914443915410.1016/j.surg.2005.09.012CrucittiF.BellantoneR.FerranteA.BoscheriniM.CrucittiP.CarboneG.CasacciaM.CampisiC.CavallaroA.SapienzaP.Del GaudioA.SolidoroG.DettoriG.MarognaP.Di GiovanniV.ColliR.DogliettoG.GozzettiG.MaldarizziF.The italian registry for adrenal cortical carcinoma: analysis of a multiinstitutional series of 129 patients199611921611702-s2.0-002967095510.1016/S0039-6060(96)80164-4TerzoloM.PiaA.BerrutiA.OsellaG.AlìA.CarboneV.TestaE.DogliottiL.AngeliA.Low-dose monitored mitotane treatment achieves the therapeutic range with manageable side effects in patients with adrenocortical cancer2000856223422382-s2.0-003445710710.1210/jc.85.6.2234TerzoloM.AngeliA.FassnachtM.Adjuvant mitotane treatment for adrenocortical carcinoma20073562323722380KendrickM. L.LloydR.EricksonL.FarleyD. R.GrantC. S.ThompsonG. B.RowlandC.YoungW. F.Van HeerdenJ. A.Adrenocortical carcinoma: surgical progress or status quo?200113655435492-s2.0-0035022726HenryJ. F.SebagF.IacoboneM.MirallieE.Results of laparoscopic adrenalectomy for large and potentially malignant tumors2002268104310472-s2.0-003668854410.1007/s00268-002-6666-0PorpigliaF.FioriC.TarabuzziR.GiraudoG.GarroneC.MorinoM.FontanaD.ScarpaR. M.Is laparoscopic adrenalectomy feasible for adrenocortical carcinoma or metastasis?2004947102610292-s2.0-964429150110.1111/j.1464-410X.2004.05098.xCorcioneF.MirandaL.MarzanoE.CapassoP.CuccurulloD.SettembreA.PirozziF.Laparoscopic adrenalectomy for malignant neoplasm: our experience in 15 cases20051968418442-s2.0-2404449160510.1007/s00464-004-9161-xPalazzoF. F.SebagF.SierraM.IppolitoG.SouteyrandP.HenryJ. F.Long-term outcome following laparoscopic adrenalectomy for large solid adrenal cortex tumors20063058938982-s2.0-3364654467910.1007/s00268-005-0288-2LombardiC. P.RaffaelliM.De CreaC.BellantoneR.Role of laparoscopy in the management of adrenal malignancies20069421281312-s2.0-3374712067810.1002/jso.20599LiaoC. H.ChuehS. C.LaiM. K.HsiaoP. J.ChenJ.Laparoscopic adrenalectomy for potentially malignant adrenal tumors greater than 5 centimeters2006918308030832-s2.0-3374772752110.1210/jc.2005-2420NoccaD.AggarwalR.MathieuA.BlancP. M.DenèveE.SalsanoV.FigueiraG.SandersG.DomergueJ.MillatB.FabreP. R.Laparoscopic surgery and corticoadrenalomas2007218137313762-s2.0-3454718496410.1007/s00464-007-9218-8RamacciatoG.MercantiniP.TorreM. L.BenedettoF. D.ErcolaniG.RavaioliM.PiccoliM.MelottiG.Is laparoscopic adrenalectomy safe and effective for adrenal masses larger than 7 cm?20082225165212-s2.0-3904912924610.1007/s00464-007-9508-1BrixD.AllolioB.FenskeW.Laparoscopic versus open adrenalectomy for adrenocortical carcinoma: surgical and oncologic outcome in 152 patients2010586e532-s2.0-7804947450910.1016/j.eururo.2010.09.001MillerB. S.AmmoriJ. B.GaugerP. G.BroomeJ. T.HammerG. D.DohertyG. M.Laparoscopic resection is inappropriate in patients with known or suspected adrenocortical carcinoma2010346138013852-s2.0-7795555217710.1007/s00268-010-0532-2LeeJ. E.BergerD. H.El-NaggarA. K.HickeyR. C.Vassilopoulou-SellinR.GagelR. F.BurgessM. A.EvansD. B.MoleyJ.PasiekaJ.CapuzziD.PrinzR.Surgical management, DNA content, and patient survival in adrenal cortical carcinoma19951186109010982-s2.0-002882814910.1016/S0039-6060(05)80119-9SchulickR. D.BrennanM. F.Long-term survival after complete resection and repeat resection in patients with adrenocortical carcinoma1999687197262-s2.0-0033396346SchteingartD. E.DohertyG. M.GaugerP. G.GiordanoT. J.HammerG. D.KorobkinM.WordenF. P.Management of patients with adrenal cancer: recommendations of an international consensus conference20051236676802-s2.0-1764439969110.1677/erc.1.01029ChicheL.DoussetB.KiefferE.ChapuisY.Adrenocortical carcinoma extending into the inferior vena cava: presentation of a 15-patient series and review of the literature2006139115272-s2.0-2914445202810.1016/j.surg.2005.05.014ReibetanzJ.JurowichC.ErdoganI.Impact of lymphadenectomy on the oncologic outcome of patients with adrenocortical carcinoma20122552363369BellantoneR.FerranteA.BoscheriniM.LombardiC. P.CrucittiP.CrucittiF.FaviaG.BorrelliD.BoffiL.CapussottiL.CarboneG.CasacciaM.CavallaroA.Del GaudioA.DettoriG.Di GiovanniV.MazziottiA.MarranoD.MasentiE.MiccoliP.MoscaF.MussaA.PetronioR.PiatG.RubertiU.SerioG.MarzanoL.Role of reoperation in recurrence of adrenal cortical carcinoma: results from 188 cases collected in the Italian National Registry for Adrenal Cortical Carcinoma19971226121212182-s2.0-1314426071510.1016/S0039-6060(97)90229-4IcardP.ChapuisY.AndreassianB.BernardA.ProyeC.Adrenocortical carcinoma in surgically treated patients: a retrospective study on 156 cases by the French Association of Endocrine Surgery199211269729802-s2.0-0027087416SmithC. D.WeberC. J.AmersonJ. R.Laparoscopic adrenalectomy: new gold standard19992343893962-s2.0-0032975465GillI. S.The case for laparoscopic adrenalectomy200116624294362-s2.0-0034947335PorpigliaF.FioriC.DaffaraF.ZaggiaB.BollitoE.VolanteM.BerrutiA.TerzoloM.Retrospective evaluation of the outcome of open versus laparoscopic adrenalectomy for stage I and II adrenocortical cancer20105758738782-s2.0-7794948695410.1016/j.eururo.2010.01.036LombardiC. P.RaffaelliM.BoniardiM.Adrenocortical carcinoma: effect of hospital volume on patient outcome20123972201207ParkH. S.RomanS. A.SosaJ. A.Outcomes from 3144 adrenalectomies in the United States: which matters more, surgeon volume or specialty?200914411106010672-s2.0-7274911428010.1001/archsurg.2009.191SchulickR. D.BrennanM. F.Adrenocortical carcinoma199917126342-s2.0-0033069954LutonJ. P.CerdasS.BillaudL.ThomasG.GuilhaumeB.BertagnaX.LaudatM. H.LouvelA.ChapuisY.BlondeauP.BonninA.BricaireH.Clinical features of adrenocortical carcinoma, prognostic factors, and the effect of mitotane therapy199032217119512012-s2.0-0025248241HutterA. M.Jr.KayhoeD. E.Adrenal cortical carcinoma. Clinical features of 138 patients19664145725802-s2.0-0013961931LipsettM. B.HertzR.RossG. T.Clinical and pathophysiologic aspects of adrenocortical carcinoma19633533743832-s2.0-0001531986CohnK.GottesmanL.BrennanM.Adrenocortical carcinoma19861006117011772-s2.0-0022878520PercarpioB.KnowltonA. H.Radiation therapy of adrenal corticol carcinoma19761542882922-s2.0-0017108917RodgersS. E.Adrenocortical carcinoma2006153535553PolatB.FassnachtM.PfreundnerL.GuckenbergerM.BratengeierK.JohanssenS.KennW.HahnerS.AllolioB.FlentjeM.Radiotherapy in adrenocortical carcinoma200911513281628232-s2.0-6764962202510.1002/cncr.24331HermsenI. G. C.GroenenY. E.DercksenM. W.TheuwsJ.HaakH. R.Response to radiation therapy in adrenocortical carcinoma201033107127142-s2.0-7995166787910.3275/6904MilgromS. A.GoodmanK. A.The role of radiation therapy in the management of adrenal carcinoma and adrenal metastases20121065647650SabolchA.FengM.GriffithK.HammerG.DohertyG.Ben-JosefE.Adjuvant and definitive radiotherapy for adrenocortical carcinoma2011805147714842-s2.0-7996010431910.1016/j.ijrobp.2010.04.030FassnachtM.HahnerS.PolatB.KoschkerA. C.KennW.FlentjeM.AllolioB.Efficacy of adjuvant radiotherapy of the tumor bed on local recurrence of adrenocortical carcinoma20069111450145042-s2.0-3375152923210.1210/jc.2006-1007SchteingartD. E.Adjuvant mitotane therapy of adrenal cancer—use and controversy200735623241524182-s2.0-3424999679210.1056/NEJMe078087LafeminaJ.BrennanM. F.Adrenocortical carcinoma: past, present, and future20121065586594HaakH. R.HermansJ.Van de VeldeC. J. H.LentjesE. G. W. M.GoslingsB. M.FleurenG. J.KransH. M. J.Optimal treatment of adrenocortical carcinoma with mitotane: results in a consecutive series of 96 patients19946959479512-s2.0-0028208020van SlootenH.MoolenaarA. J.Van SetersA. P.SmeenkD.The treatment of adenocortical carcinoma with o,p′-DDD: prognostic simplications of serum level monitoring198420147532-s2.0-0021289017BaudinE.PellegritiG.BonnayM.Impact of monitoring plasma 1, 1-dichlorodiphenildichloroethane (o, p′DDD) levels on the treatment of patients with adrenocortical carcinoma200192613851392FaggianoA.LeboulleuxS.YoungJ.SchlumbergerM.BaudinE.Rapidly progressing high o,p'DDD doses shorten the time required to reach the therapeutic threshold with an acceptable tolerance: preliminary results20066411101132-s2.0-3364493469710.1111/j.1365-2265.2005.02403.xDaffaraF.de FranciaS.ReimondoG.ZaggiaB.AroasioE.PorpigliaF.VolanteM.TermineA.di CarloF.DogliottiL.AngeliA.BerrutiA.TerzoloM.Prospective evaluation of mitotane toxicity in adrenocortical cancer patients treated adjuvantly2008154104310532-s2.0-5824910303410.1677/ERC-08-0103Vassilopoulou-SellinR.GuineeV. F.KleinM. J.TaylorS. H.HessK. R.SchultzP. N.SamaanN. A.Impact of adjuvant mitotane on the clinical course of patients with adrenocortical cancer19937110311931232-s2.0-0027190328BodieB.NovickA. C.PontesJ. E.StraffonR. A.MontieJ. E.BabiakT.SheelerL.SchumacherP.The Cleveland Clinic experience with adrenal cortical carcinoma198914122572602-s2.0-0024582517Kasperlik-ZaluskaA. A.MigdalskaB. M.ZgliczyńskiS.MakowskaA. M.Adrenocortical carcinoma. A clinical study and treatment results of 52 patients1995751025872591BerrutiA.FassnachtM.BaudinE.HammerG.HaakH.LeboulleuxS.SkogseidB.AllolioB.TerzoloM.Adjuvant therapy in patients with adrenocortical carcinoma: a position of an international panel20102823e401e4022-s2.0-7795726204410.1200/JCO.2009.27.5958HahnerS.FassnachtM.Mitotane for adrenocortical carcinoma treatment2005643863942-s2.0-17644420335WängbergB.Khorram-ManeshA.JanssonS.NilssonB.NilssonO.JakobssonC. E.LindstedtS.OdénA.AhlmanH.The long-term survival in adrenocortical carcinoma with active surgical management and use of monitored mitotane20101712652722-s2.0-7744913026210.1677/ERC-09-0190IliasI.AlevizakiM.PhilippouG.AnastasiouE.SouvatzoglouA.Sustained remission of metastatic adrenal carcinoma during long-term administration of low-dose mitotane20012475325352-s2.0-0034927782GonzalezR. J.TammE. P.NgC.PhanA. T.Vassilopoulou-SellinR.PerrierN. D.EvansD. B.LeeJ. E.Response to mitotane predicts outcome in patients with recurrent adrenal cortical carcinoma200714268678752-s2.0-3664900534710.1016/j.surg.2007.09.006KhanT. S.ImamH.JuhlinC.SkogseidB.GröndalS.TibblinS.WilanderE.ÖbergK.ErikssonB.Streptozocin and o,p′DDD in the treatment of adrenocortical cancer patients: long-term survival in its adjuvant use20001110128112872-s2.0-003376789110.1023/A:1008377915129BerrutiA.TerzoloM.SperoneP.PiaA.Della CasaS.GrossD. J.CarnaghiC.CasaliP.PorpigliaF.ManteroF.ReimondoG.AngeliA.DogliottiL.Etoposide, doxorubicin and cisplatin plus mitotane in the treatment of advanced adrenocortical carcinoma: a large prospective phase II trial20051236576662-s2.0-2694446863510.1677/erc.1.01025FassnachtM.TerzoloM.AllolioB.Combination chemotherapy in advanced adrenocortical carcinoma20123662321892197GiordanoT. J.ThomasD. G.KuickR.LizynessM.MisekD. E.SmithA. L.SandersD.AljundiR. T.GaugerP. G.ThompsonN. W.TaylorJ. M. G.HanashS. M.Distinct transcriptional profiles of adrenocortical tumors uncovered by DNA microarray analysis200316225215312-s2.0-0037331277de FraipontF.El AtifiM.CherradiN.MoigneG. L.DefayeG.HoulgatteR.BertheratJ.BertagnaX.PlouinP. F.BaudinE.BergerF.GicquelC.ChabreO.FeigeJ. J.Gene expression profiling of human adrenocortical tumors using complementary deoxyribonucleic acid microarrays identifies several candidate genes as markers of malignancy2005903181918292-s2.0-2014438684810.1210/jc.2004-1075SoonP. S. H.GillA. J.BennD. E.ClarksonA.RobinsonB. G.McDonaldK. L.SidhuS. B.Microarray gene expression and immunohistochemistry analyses of adrenocortical tumors identify IGF2 and Ki-67 as useful in differentiating carcinomas from adenomas20091625735832-s2.0-6765048039610.1677/ERC-08-0237Velázquez-FernándezD.LaurellC.GeliJ.HöögA.OdebergJ.KjellmanM.LundebergJ.HambergerB.NilssonP.BäckdahlM.Expression profiling of adrenocortical neoplasms suggests a molecular signature of malignancy20051386108710942-s2.0-2914443776010.1016/j.surg.2005.09.031SlaterE. P.DiehlS. M.LangerP.SamansB.RamaswamyA.ZielkeA.BartschD. K.Analysis by cDNA microarrays of gene expression patterns of human adrenocortical tumors200615445875982-s2.0-3364604344910.1530/eje.1.02116SzabóP. M.TamásiV.MolnárV.AndrásfalvyM.TömbölZ.FarkasR.KövesdiK.PatócsA.TóthM.SzalaiC.FalusA.RáczK.IgazP.Meta-analysis of adrenocortical tumour genomics data: novel pathogenic pathways revealed20102921316331722-s2.0-7795295320310.1038/onc.2010.80GicquelC.BertagnaX.GastonV.CosteJ.LouvelA.BaudinE.BertheratJ.ChapuisY.DuclosJ. M.SchlumbergerM.PlouinP. F.LutonJ. P.Le BoucY.Molecular markers and long-term recurrences in a large cohort of patients with sporadic adrenocortical tumors20016118676267672-s2.0-0035884186GicquelC.Raffin-SansonM. L.GastonV.BertagnaX.PlouinP. F.SchlumbergerM.LouvelA.LutonJ. P.Le BoucY.Structural and functional abnormalities at 11p15 are associated with the malignant phenotype in sporadic adrenocortical tumors: study on a series of 82 tumors1997828255925652-s2.0-003084073810.1210/jc.82.8.2559AroraA.ScholarE. M.Role of tyrosine kinase inhibitors in cancer therapy200531539719792-s2.0-2754447931810.1124/jpet.105.084145QuinklerM.HahnerS.WortmannS.JohanssenS.AdamP.RitteC.StrasburgerC.AllolioB.FassnachtM.Treatment of advanced adrenocortical carcinoma with erlotinib plus gemcitabine2008936205720622-s2.0-4514911073710.1210/jc.2007-2564WortmannS.QuinklerM.RitterC.KroissM.JohanssenS.HahnerS.AllolioB.FassnachtM.Bevacizumab plus capecitabine as a salvage therapy in advanced adrenocortical carcinoma201016223493562-s2.0-7514914301510.1530/EJE-09-0804FassnachtM.KreisslM. C.WeismannD.AllolioB.New targets and therapeutic approaches for endocrine malignancies200912311171412-s2.0-6574912053210.1016/j.pharmthera.2009.03.013BerrutiA.FerreroA.SperoneP.DaffaraF.ReimondoG.PapottiM.DogliottiL.AngeliA.TerzoloM.Emerging drugs for adrenocortical carcinoma20081334975092-s2.0-5354912606010.1517/14728214.13.3.497LaurellC.Velázquez-FernándezD.LindstenK.Transcriptional profiling enables molecular classification of adrenocortical tumours20091611141152Fernandez-RanvierG. G.WengJ.YehR. F.KhanafsharE.SuhI.BarkerC.DuhQ. Y.ClarkO. H.KebebewE.Identification of biomarkers of adrenocortical carcinoma using genomewide gene expression profiling200814398418462-s2.0-5224910961010.1001/archsurg.143.9.841HaluskaP.WordenF.OlmosD.YinD.SchteingartD.BatzelG. N.PaccagnellaM. L.De BonoJ. S.GualbertoA.HammerG. D.Safety, tolerability, and pharmacokinetics of the anti-IGF-1R monoclonal antibody figitumumab in patients with refractory adrenocortical carcinoma20106547657732-s2.0-7574910223110.1007/s00280-009-1083-9MulvihillM. J.CookeA.Rosenfeld-FranklinM.BuckE.ForemanK.LandfairD.OconnorM.PirrittC.SunY.YaoY.ArnoldL. D.GibsonN. W.JiQ. S.Discovery of OSI-906: a selective and orally efficacious dual inhibitor of the IGF-1 receptor and insulin receptor200916115311712-s2.0-7795206025010.4155/fmc.09.89FaivreS.KroemerG.RaymondE.Current development of mTOR inhibitors as anticancer agents2006586716882-s2.0-3374663766010.1038/nrd2062DoghmanM.El WakilA.CardinaudB.ThomasE.WangJ.ZhaoW.Peralta-Del ValleM. H. C.FigueiredoB. C.ZambettiG. P.LalliE.Regulation of insulin-like growth factor-mammalian target of rapamycin signaling by MicroRNA in childhood adrenocortical tumors20107011466646752-s2.0-7795316829410.1158/0008-5472.CAN-09-3970NaingA.KurzrockR.BurgerA.Phase I trial of cixutumumab combined with temsirolimus in patients with advanced cancer2011171860526060MacDonaldB. T.TamaiK.HeX.Wnt/β-catenin signaling: components, mechanisms, and diseases20091719262-s2.0-6765023089610.1016/j.devcel.2009.06.016AssieG.GiordanoT. J.BertheratJ.Gene expression profiling in adrenocortical neoplasia20123511111117RagazzonB.AssiéG.BertheratJ.Transcriptome analysis of adrenocortical cancers: from molecular classification to the identification of new treatments2011182R15R272-s2.0-7995316534210.1530/ERC-10-0220TissierF.CavardC.GroussinL.PerlemoineK.FumeyG.HagneréA. M.René-CorailF.JullianE.GicquelC.BertagnaX.Vacher-LavenuM. C.PerretC.BertheratJ.Mutations of β-catenin in adrenocortical tumors: activation of the Wnt signaling pathway is a frequent event in both benign and malignant adrenocortical tumors20056517762276272-s2.0-2474445419710.1158/0008-5472.CAN-05-0593BerthonA.Sahut-BarnolaI.Lambert-LanglaisS.de JoussineauC.Damon-SoubeyrandC.LouisetE.TaketoM. M.TissierF.BertheratJ.Lefrançois-MartinezA. M.MartinezA.ValP.Constitutive β-catenin activation induces adrenal hyperplasia and promotes adrenal cancer development2010198156115762-s2.0-7795230054110.1093/hmg/ddq029SchimmerB. P.WhiteP. C.Minireview: steroidogenic factor 1: its roles in differentiation, development, and disease2010247132213372-s2.0-7795483294410.1210/me.2009-0519FigueiredoB. C.CavalliL. R.PianovskiM. A.Amplification of the steroidogenic factor 1 gene in childhood adrenocortical tumors2005902615619PianovskiM. A. D.CavalliL. R.FigueiredoB. C.SantosS. C. L.DoghmanM.RibeiroR. C.OliveiraA. G.MichalkiewiczE.RodriguesG. A.ZambettiG.HaddadB. R.LalliE.SF-1 overexpression in childhood adrenocortical tumours2006428104010432-s2.0-3364652192410.1016/j.ejca.2006.01.022DoghmanM.KarpovaT.RodriguesG. A.ArhatteM.De MouraJ.CavalliL. R.VirolleV.BarbryP.ZambettiG. P.FigueiredoB. C.HeckertL. L.LalliE.Increased steroidogenic factor-1 dosage triggers adrenocortical cell proliferation and cancer20072112296829872-s2.0-3684907320210.1210/me.2007-0120DoghmanM.CazarethJ.DouguetD.MadouxF.HodderP.LalliE.Inhibition of adrenocortical carcinoma cell proliferation by steroidogenic factor-1 inverse agonists2009946217821832-s2.0-6674917939610.1210/jc.2008-2163DemeureM. J.BusseyK. J.KirschnerL. S.Targeted therapies for adrenocortical carcinoma: IGF and beyond201126385392RonchiC. L.SbieraS.KrausL.WortmannS.JohanssenS.AdamP.WillenbergH. S.HahnerS.AllolioB.FassnachtM.Expression of excision repair cross complementing group 1 and prognosis in adrenocortical carcinoma patients treated with platinum-based chemotherapy20091639079182-s2.0-7274910091010.1677/ERC-08-0224MistryP.StewartA. J.DangerfieldW.OkijiS.LiddleC.BootleD.PlumbJ. A.TempletonD.CharltonP.In vitro and in vivo reversal of P-glycoprotein-mediated multidrug resistance by a novel potent modulator, XR957620016127497582-s2.0-0035863315WalkerJ.MartinC.CallaghanR.Inhibition of P-glycoprotein function by XR9576 in a solid tumour model can restore anticancer drug efficacy20044045946052-s2.0-124233894310.1016/j.ejca.2003.09.036